CompletedPhase 2NCT00107419
S0423 Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma
Studying Chondrosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SWOG Cancer Research Network
- Principal Investigator
- Warren A. Chow, MDCity of Hope Comprehensive Cancer Center
- Intervention
- pemetrexed disodium(drug)
- Enrollment
- 75 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2005 – 2009
Study locations (30)
- USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
- Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center, Savannah, Georgia, United States
- Rush-Copley Cancer Care Center, Aurora, Illinois, United States
- Joliet Oncology-Hematology Associates, Limited - West, Joliet, Illinois, United States
- Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, United States
- Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois, United States
- CCOP - Carle Cancer Center, Urbana, Illinois, United States
- Saint Anthony Memorial Health Centers, Michigan City, Indiana, United States
- Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, United States
- Tammy Walker Cancer Center at Salina Regional Health Center, Salina, Kansas, United States
- Cancer Research Center at Boston Medical Center, Boston, Massachusetts, United States
- CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States
- St. John's Regional Health Center, Springfield, Missouri, United States
- Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States
- CCOP - Montana Cancer Consortium, Billings, Montana, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00107419 on ClinicalTrials.govOther trials for Chondrosarcoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNANCT07360964Clear Cell Chondrosarcoma in ItalyIstituto Ortopedico Rizzoli
- RECRUITINGNCT07315542Diagnostic and Therapeutic Targets in Cartilaginous TumoursSt. Anne's University Hospital Brno, Czech Republic
- RECRUITINGEARLY PHASE1NCT06645808PET-imaging of Two Vartumabs in Patients With Solid TumorsVar2 Pharmaceuticals
- RECRUITINGPHASE3NCT06127407Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment RegimenServier Bio-Innovation LLC
- RECRUITINGNCT06486506Proximal Femur Reconstruction Following Resection of Primary Bone Tumors: Analysis of the Clinical and Radiographic ResultsCostantino Errani
- RECRUITINGPHASE2NCT06176989Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base TumorsNational Cancer Institute (NCI)
- RECRUITINGNANCT06387485A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative PlanningRicoh USA, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT05836571Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue SarcomaNational Cancer Institute LAO